Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 278 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Arthropathy of Hip Joint Clear all

Conditions: Osteoarthritis, Hip, Osteoarthritis, Knee, Lower Back Pain, Pain
Interventions: Oxycodone CR, Tapentadol (CG5503) ER; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 1,123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 40
States / cities: Mesa, Arizona • Tucson, Arizona • Anaheim, California + 37 more

Conditions: Chronic Low Back Pain, Osteoarthritis
Interventions: Fasinumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 56
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 47 more

Conditions: Osteoarthritis, Pain
Interventions: Patient may be able to put weight on the operated leg; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Osteoarthritis, Knee
Interventions: OM1 Dell Shared Decision Making Tool, Education material from OM1 Dell Shared Decision Making Tool; Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 45 Years to 89 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Osteoarthritis
Interventions: tanezumab 10 mg, tanezumab 5 mg, naproxen, placebo; Biological · Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 849 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 95
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 69 more

Conditions: Hip Osteoarthritis, Surgery
Interventions: total hip arthroplasty; Procedure
Lead sponsor: Orthopedic One; Other
Eligibility: 18 Years to 75 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Dublin, Ohio

Conditions: Dysplasia; Hip
Interventions: Spica cast, Rhino brace; Device
Lead sponsor: Yale University; Other
Eligibility: 0 Months to 18 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Osteoarthritis
Interventions: Buprenorphine transdermal patch, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 44
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Osteoarthritis, Hip, Hip Disease
Interventions: MAKO THA 4.0 System; Device
Lead sponsor: American Hip Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Des Plaines, Illinois

Conditions: Osteoarthritis
Interventions: Diclofenac, Placebo; Drug
Lead sponsor: Iroko Pharmaceuticals, LLC; Industry
Eligibility: 40 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 40
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 31 more

Conditions: Labrum Injury of the Hip Joint, Hip Arthroscopy, Femoroacetabular Impingement Syndrome
Interventions: Non-Absorbable Sutures, Absorbable Suture; Device
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Osteoarthritis, Rheumatoid Arthritis, Arthritis, Avascular Necrosis, Acute Fracture
Interventions: Acetabular cup; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: Not listed
Enrollment: 1,593 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2012
U.S. locations: 1
States / cities: Warsaw, Indiana

Conditions: Osteoarthritis, Hip
Interventions: ReNu™ Injection; Other
Lead sponsor: NuTech Medical, Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Redwood City, California • Chicago, Illinois

Conditions: Subchondral Cysts, Subchondral Bone Edema, Bone Marrow Edema, Insufficiency Fractures, Avascular Necrosis of Hip, Femoroacetabular Impingement, Dysplasia; Hip
Interventions: Subchondroplasty Procedure with AccuFill; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 6
States / cities: Rancho Mirage, California • Gulf Breeze, Florida • Rockford, Illinois + 3 more

Conditions: Osteoarthritis
Interventions: Mini Incision Approach, 2 Incision Approach; Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Joint Diseases, Osteoarthritis, Hip, Rheumatoid Arthritis, Psoriatic Arthritis, Avascular Necrosis of Hip
Interventions: Routine Total Hip Arthroplasty; Device
Lead sponsor: Ortho Development Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Osteoarthritis, Degenerative Joint Disease
Interventions: Bupivicaine + epinephrine, Bupivacaine, Ropivacaine, Ketorolac, Clonidine Injection; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Osteoarthritis, Osteoarthritis, Hip
Interventions: Naproxcinod, Naproxen, Placebo; Drug
Lead sponsor: NicOx; Industry
Eligibility: 40 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 36
States / cities: Mobile, Alabama • Montgomery, Alabama • Tuscaloosa, Alabama + 33 more

Conditions: Hip Dysplasia
Interventions: PAO with hip arthroscopy, PAO without hip arthroscopy; Procedure
Lead sponsor: Ottawa Hospital Research Institute; Other
Eligibility: 16 Years to 50 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 4
States / cities: Chicago, Illinois • Royal Oak, Michigan • St Louis, Missouri + 1 more

Conditions: Osteoarthritis
Interventions: Meloxicam Test Capsules; Drug
Lead sponsor: Iroko Pharmaceuticals, LLC; Industry
Eligibility: 40 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Carmichael, California + 32 more

Conditions: Osteoarthritis, Hip
Interventions: Dexamethasone, Bupivacaine, Epinephrine, Lumbar Plexus Nerve Block, Saline; Drug · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 90 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Osteoarthritis of the Hip
Interventions: Resonator device; Device
Lead sponsor: pico-tesla Magnetic Therapies, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Femoroacetabular Impingement Syndrome, Acetabular Labral Tear
Interventions: Hip brace; Device
Lead sponsor: University of Washington; Other
Eligibility: 14 Years to 60 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Arthroplasty, Replacement, Hip
Interventions: Tritanium® Primary Acetabular Shell; Device
Lead sponsor: Stryker Orthopaedics; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 7
States / cities: St. Helena, California • Tampa, Florida • Lexington, Kentucky + 4 more

Search by objective public record fields.

A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

Safety of Non-delayed Weight Bearing After Total Hip Replacement With Non-Cemented Fiber Metal Taper Stem

The Impact of a Technology-enabled Decision Aid, for Patients With Hip and Knee Osteoarthritis on Decision Quality, Level of Shared Decision-making, Patient Satisfaction and Magnitude of Limitations

Tanezumab in Osteoarthritis of the Hip or Knee (2)

Physical Therapy Following Total Hip Arthroplasty

Spica Cast Duration for DDH

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

Multicenter Study for Robotic Arm-assisted THA 4.0 System: Hip Spine Relationship

Study of Diclofenac Capsules to Treat Osteoarthritis Pain

Absorbable vs Non-Absorbable Sutures for Hip Capsular Closure

Clinical Study Evaluating an Acetabular Cup System After Total Hip Replacement

ReNu™ Injection to Treat Hip Osteoarthritis Study

SCP Hip Outcomes Study

Study Comparing Mini-Incision Versus 2-Incision Approach for Total Hip Replacement

Survivorship and Patient Outcomes of Primary Total Hip Arthroplasty With the Ovation Hip System

Efficacy of Intraoperative Injections on Postoperative Pain Control During Total Hip Replacement

Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip

Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology

Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip

Systemic Steroids for Peripheral Nerve Blocks

Low Level Magnetic Fields for the Treatment of Osteoarthritis of the Hip

Postoperative Hip Bracing After Hip Arthroscopy

Tritanium® Primary Acetabular Shell Study